Xulane Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Xulane Availability in 2026

Xulane (Norelgestromin 150 mcg/Ethinyl Estradiol 35 mcg transdermal system) remains one of the most commonly prescribed contraceptive patches in the United States. However, providers across the country are hearing from patients who cannot locate it at their pharmacies. This article provides a clinical and logistical overview of the current Xulane availability landscape to help you manage prescribing decisions and patient expectations.

Background: Xulane in the U.S. Market

Xulane is the branded generic of Ortho Evra, which was discontinued by Janssen in 2014. It is manufactured by Mylan Pharmaceuticals, now operating under the Viatris umbrella. Xulane was FDA-approved in April 2014 and has been the dominant contraceptive patch product since Ortho Evra's withdrawal.

The U.S. contraceptive patch market is small, with only three products currently available:

• Xulane (Norelgestromin/Ethinyl Estradiol) — Mylan/Viatris
• Zafemy (Norelgestromin/Ethinyl Estradiol) — another Ortho Evra generic
• Twirla (Levonorgestrel/Ethinyl Estradiol) — Agile Therapeutics

This limited manufacturer base is a key factor in the availability challenges described below.

Shortage Timeline and Current Status

As of early 2026, Xulane is not listed on the FDA Drug Shortage Database. Viatris has not issued a formal shortage notification. However, anecdotal reports from patients and pharmacists indicate persistent spot shortages — localized stockouts driven by distributor allocation, pharmacy ordering patterns, and demand fluctuations.

Key timeline points:

• 2014: Ortho Evra discontinued; Xulane enters market as primary contraceptive patch.
• 2020–2022: COVID-era supply chain disruptions affect pharmaceutical manufacturing broadly, including transdermal products.
• 2023–2024: Sporadic patient reports of difficulty finding Xulane at chain pharmacies.
• 2025: Viatris completes Phase 3 trial for Xulane Lo (lower-dose patch). Some regions continue to report intermittent availability issues.
• 2026: No formal shortage, but spot shortages persist. Xulane Lo may be submitted for FDA review.

Prescribing Implications

The current supply situation has several implications for prescribers:

Patient Adherence

When patients cannot fill their Xulane prescription promptly, they face a gap in contraceptive coverage. Unlike oral contraceptives — where a patient might miss a day and catch up — a delayed patch application introduces a more significant adherence challenge, especially for patients who need backup contraception during the patch-free interval.

BMI Considerations

Xulane carries a boxed warning noting that it is contraindicated in women with a BMI ≥ 30 kg/m² due to increased venous thromboembolism (VTE) risk. It may also be less effective in women weighing 198 lbs (90 kg) or more. When considering alternatives, providers should factor in the patient's BMI and the weight-related limitations of each product.

Therapeutic Alternatives

When Xulane is unavailable, consider the following:

• Zafemy: Same active ingredients as Xulane. Requires a new prescription but is the closest therapeutic equivalent.
• Twirla: Different progestin (Levonorgestrel) and lower estrogen dose (30 mcg EE/day). Not interchangeable with Xulane. May be appropriate for patients who tolerate a lower estrogen dose.
• NuvaRing or generic (Etonogestrel/EE vaginal ring): Monthly non-oral combined hormonal contraceptive. Good option for patients who want non-daily dosing without a patch.
• Oral CHCs: Widely available. Best for patients who are willing to switch to daily dosing.

For a patient-facing overview of these options, direct patients to alternatives to Xulane.

Availability Picture: Where to Find Xulane

The availability of Xulane varies significantly by pharmacy type, geography, and distributor:

• Chain pharmacies (CVS, Walgreens, Rite Aid) stock based on local demand algorithms. Low-volume stores may not keep Xulane on hand.
• Independent pharmacies often have more flexible ordering and may use different wholesale distributors.
• Mail-order pharmacies typically maintain larger inventories and may be less affected by local spot shortages.
• Health system pharmacies (clinic-based, hospital outpatient) may carry Xulane if their patient population supports it.

Cost and Access Considerations

Cost can be a barrier to access even when supply is available:

• Cash price: Approximately $100–$200/month for a box of 3 patches.
• With discount cards: GoodRx brings the price to approximately $47; SingleCare to approximately $77.
• ACA mandate: Most commercial insurance plans cover contraceptives, including Xulane, at no cost-sharing. However, some plans apply prior authorization or step therapy requirements.
• Viatris savings card: $0 on first fill, $15 on subsequent fills for commercially insured patients. Maximum $425/year. Not valid for government insurance.
• Viatris Patient Assistance Program: Available for eligible uninsured or underinsured patients through viatris.com.

For provider guidance on helping patients save, see how to help patients save money on Xulane.

Tools and Resources for Providers

Several resources can help you and your patients navigate Xulane availability:

• Medfinder for Providers: Check real-time pharmacy availability of Xulane and other medications. Share with patients so they can locate nearby pharmacies with stock.
• Xulane HCP site: xulanehcp.com — prescribing information, savings card enrollment, and clinical resources.
• FDA Drug Shortage Database: Monitor for any formal shortage declarations at fda.gov/drug-shortages.

Having a workflow for quickly checking availability and communicating alternatives to patients can significantly reduce the disruption caused by spot shortages. See our companion article: how to help your patients find Xulane in stock.

Looking Ahead

The contraceptive patch market may see meaningful developments in 2026:

• Xulane Lo: Viatris's lower-dose patch (150 mcg Norelgestromin / 17.5 mcg EE per day) showed positive Phase 3 results in 2025 and is expected to be submitted for FDA review. If approved, it would add another option — particularly attractive for patients concerned about estrogen-related side effects.
• Broader market dynamics: Growing patient demand for non-daily, non-oral contraceptive methods may encourage additional manufacturers to enter the patch market over time.

Final Thoughts

Xulane remains a valuable contraceptive option, but its limited manufacturer base and pharmacy-level supply variability create real challenges for patients and prescribers alike. Proactive communication with patients about availability, alternatives, and cost-saving tools can minimize gaps in coverage and maintain contraceptive continuity.

Encourage patients to use Medfinder to check stock before heading to the pharmacy, and consider having a prescribing plan B in place for your Xulane patients in case supply disruptions continue. For patient-facing information on the shortage, direct them to Xulane shortage update: what patients need to know in 2026.